文献速递泌尿生殖MRUS

软件辅助MRI-TRUS融合引导经会阴前列腺活检:能否省略对侧系统活检

Software-assisted magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion-guided transperineal prostate biopsy: is there still a need for contralateral systematic biopsy?
PubMed 文献 · Clin Radiol · 2026-06-09

本研究为前瞻性单中心研究,纳入582例单侧PI-RADS v2.1评分3-5分的MRI可见前列腺病灶患者,均行MRI-TRUS融合引导经会阴联合活检。比较靶向活检加同侧系统活检与联合活检对临床有意义前列腺癌的检出率。结果显示两种方案检出率无统计学差异,省略对侧系统活检可减少临床无意义癌检出及穿刺针数。

要点

  • 单侧PI-RADS 3-5分病灶可考虑省略对侧系统活检
  • 靶向加同侧系统活检可检出联合活检99.5%的csPCa
  • 省略对侧系统活检可减少临床无意义前列腺癌检出

核心结论

  • 省略MRI靶病灶对侧的系统活检可在保持csPCa检出率相当的同时,降低cisPCa检出率并减少穿刺针数
  • TBx+SBxIpsi检出381/582例csPCa,相当于CBx检出csPCa的99.5%

研究设计与样本

  • 前瞻性单中心研究,共分析582次MRI-TRUS融合引导经会阴前列腺活检
  • 入组标准为MRI显示单一单侧前列腺病灶、不跨中线、PI-RADS v2.1评分3-5分
  • 联合活检方案包括5针靶向活检和10针系统活检,每侧腺体5针系统活检
  • csPCa定义为国际泌尿病理学会分级分组≥2级,cisPCa定义为ISUP分级分组1级

诊断标准与关键数值

  • CBx检出csPCa 383/582例,检出率65.8%,95%CI为61.8%-69.7%
  • TBx+SBxIpsi检出csPCa 381/582例,检出率65.5%,95%CI为61.4%-69.3%
  • 两种方案csPCa检出率比较采用McNemar检验及Holm-Bonferroni校正,P=0.4795,差异无统计学意义
  • TBx+SBxIpsi检出cisPCa 80/582例,CBx检出87/582例,P=0.0455
  • 入组患者平均年龄69±9岁

临床应用与阅片要点

  • 对MRI单侧可见病灶患者,报告可提示靶向加同侧系统活检方案具有与联合活检相当的csPCa检出效能
  • 省略对侧系统活检时可预期降低cisPCa检出,有助于减少过度诊断
  • 该策略适用于单一单侧、不跨中线的PI-RADS 3-5分前列腺病灶

局限性

  • 本研究为单中心前瞻性设计,结果外推需考虑机构操作经验与设备条件

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: Combined biopsy (CBx) of the prostate, integrating magnetic resonance imaging (MRI)-targeted biopsy (TBx) with systematic biopsy (SBx), is widely used for detecting clinically significant prostate cancer (csPCa) but carries a risk of overdiagnosis. This study evaluated whether SBxs contralateral to the MRI target can be omitted in men with unilateral MRI-visible prostate lesions by comparing CBx with targeted biopsy plus ipsilateral systematic biopsy (TBx + SBxIpsi).

MATERIALS AND METHODS: In this prospective, single-centre study, 582 magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion-guided transperineal biopsy sessions were analysed. Inclusion criteria were a single unilateral prostate lesion on MRI, not overlapping the midline, with a Prostate Imaging Reporting and Data System (PI-RADS) v2.1 score of 3-5. Patients underwent CBx, consisting of 5 TBx cores and 10 SBx cores (SBx; 5 per hemigland). Detection rates of csPCa (International Society of Urological Pathology [ISUP] grade group ≥2) and clinically insignificant prostate cancer (cisPCa, ISUP grade group 1) using TBx + SBxIpsi were compared with CBx using McNemar's test with Holm-Bonferroni correction.

RESULTS: A total of 582 men (mean age: 69 ± 9 years) underwent biopsy. CBx detected csPCa in 383 of 582 patients (65.8%; 95% confidence interval [CI]: 61.8-69.7%). TBx + SBxIpsi detected csPCa in 381 of 582 patients (65.5%; 95% CI: 61.4-69.3%), identifying 99.5% of csPCa cases detected by CBx, with no statistically significant difference (P=0.4795). Detection of cisPCa was lower with TBx + SBxIpsi than with CBx (80/582 vs. 87/582; P=0.0455).

CONCLUSION: Omitting SBxs contralateral to the MRI target maintains comparable csPCa detection while reducing cisPCa detection and the number of biopsy cores.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Claerhoudt, De Vulder, Libeert, et al. Software-assisted magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion-guided transperineal prostate biopsy: is there still a need for contralateral systematic biopsy? Clin Radiol. 2026. PMID: 42263549. doi:10.1016/j.crad.2026.107380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。